Related Experiment Video
Updated: Sep 18, 2025
04:37
Author Spotlight: Advancing Research on Candida albicans Biofilm-Associated Prosthetic Joint Infections
Published on: February 2, 2024
956
Candida glabrata Prosthetic Joint Infection Managed with Ibrexafungerp
Ella Nadarevic1, Jack McHugh1, Paschalis Vergidis1
1Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Journal of Fungi (Basel, Switzerland)
|June 25, 2025
Summary
A challenging case of resistant Candida glabrata prosthetic joint infection was treated with ibrexafungerp. Despite initial improvement, the patient relapsed, underscoring the need for new antifungal strategies.
Area of Science:
- Infectious Diseases
- Mycology
- Pharmacology
Background:
- Prosthetic joint infections (PJIs) pose significant treatment challenges, particularly those caused by drug-resistant fungi.
- Candida glabrata is an opportunistic pathogen increasingly associated with antifungal resistance, complicating therapeutic options.
Observation:
- A 60-year-old woman presented with a right shoulder PJI caused by Candida glabrata resistant to both triazole and echinocandin antifungal agents.
- The patient was treated with ibrexafungerp, a novel triterpenoid antifungal, following surgical intervention.
Findings:
- Initial treatment with ibrexafungerp led to clinical improvement in the patient's fungal PJI.
- However, the patient experienced a relapse of the infection four months after completing the ibrexafungerp treatment course.
Implications:
- This case demonstrates the complex management of multidrug-resistant Candida infections, even with novel antifungal agents.
- Further research is warranted to understand the long-term efficacy and resistance patterns associated with ibrexafungerp in treating invasive fungal infections.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
210
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
210
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
01:29Drugs for Treatment of Ulcerative Colitis in IBD
244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
01:29Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
01:18Endocarditis III: Medical Management
23
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
23